Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours

A Phase I, Open Label, Dual Centre Study To Assess The Safety And Tolerability Of AZD2281 In Combination With Bevacizumab (Avastin®) In Patients With Advanced Solid Tumours

Phase I, open label, dual centre, dose finding study to evaluate the safety and tolerability of continuous twice daily oral dosing with AZD2281 when administered in combination with Bevacizumab 10mg/kg given every 2 weeks to patients with advanced solid tumours.

Inclusion Criteria:

• Histologically confirmed metastatic cancer, not amenable to surgery or radiation therapy with curative intent
• Adequate bone marrow, kidney and liver function in accordance with laboratory parameters set out in the protocol
• Estimated life expectancy of at least 12 weeks

Exclusion Criteria:

• Disorders that may put the patient at risk of bleeding, including gastrointestinal perforation, intra-abdominal abcess, major surgery of the chest or abdomen, previous haemorrhage, coughing up blood or thrombotic event
• Hypertension (high blood pressure) or significant cardiovascular disease
• Hypersensitivity to Chinese hamster ovary cell products or other recombinant or humanised antibodies